Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay005 in healthy volunteers
NCT06908642Phase 1Completed
- Sponsor
- Tianjin Hemay Biotech
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mufemilast in chronic obstructive pulmonary disease (COPD) (7 arms), sponsored by Tianjin Hemay Biotech. Primary endpoint: Incidence of Adverse Reactions at 14 days. Started Dec 2024; status: completed.
02
Drugs
mufemilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06908642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908642.